A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.


OBJECTIVES To use a viral dynamics model to compare the effectiveness of in vivo viral inhibition of several doses of maraviroc (MVC;UK-427,857) and to use a modeling approach to support design decisions for a monotherapy study using various dosing regimens of maraviroc given with and without food. DESIGN The pharmacokinetic-pharmacodynamic model was… (More)


  • Presentations referencing similar topics